We found knockdown of CDK9 antagonized both proliferation and metastatic abilities of bladder cancer cells (Figure S1), which indicated that CDK9 was an important effector in GAS6‐AS2/miR‐298 axis. Here, CDK9 is linked to urinary bladder cancer.